OncoMatch/Clinical Trials/NCT05842785
TSN222 in Subjects With Advanced Solid Tumors or Lymphomas
Is NCT05842785 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Phase I dose escalation and Phase II-HNSCC for has a pathologically documented unresectable locally advanced or metastatic solid tumor or lymphoma.
Treatment: Phase I dose escalation · Phase II-HNSCC · Phase II-Advanced melanoma · Phase II-solid tumors or lymphomas — The study is a first-in-human \[FIH\], open-label phase 1/2 study of TSN222 in subjects with advanced solid tumors or lymphomas. This study is comprised of a Phase 1 dose escalation and Phase 2 dose expansion component.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Tumor Agnostic
Disease stage
Metastatic disease required
unresectable locally advanced or metastatic solid tumor or lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic treatment — advanced
refractory to or intolerable with at least one systemic treatment in the advanced setting
Cannot have received: systemic anti-cancer treatment
Prior systemic anti-cancer treatment (chemotherapy, biologic therapy, or targeted therapy or herbal medicine) within 3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of study drug; or prior systemic anti-tumor immunotherapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose of study drug.
Cannot have received: systemic anti-tumor immunotherapy
prior systemic anti-tumor immunotherapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose of study drug
Cannot have received: radiation therapy
Radical radiation within 4 weeks prior to the first dose of study drug; palliative radiotherapy to a non-target lesion within 2 weeks prior to the first dose of study drug.
Cannot have received: investigational agent/device
Has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks prior to the first dose of study drug.
Cannot have received: major surgery
Major surgery within 4 weeks prior to first dose of study drug.
Lab requirements
Blood counts
Adequate bone marrow function
Kidney function
estimated creatinine clearance ≥ 50 mL/min as calculated using Cockcroft-Gault formula
Liver function
Adequate liver function
Adequate bone marrow function; Adequate renal function: estimated creatinine clearance ≥ 50 mL/min as calculated using Cockcroft-Gault formula; Adequate liver function; Blood albumin ≥ 30g/L; Adequate coagulation function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify